Bioventus (BVS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
Meeting opened with a reminder about forward-looking statements and associated risks under U.S. Securities Laws.
Board members, executive officers, and the independent auditor were introduced at the start.
The agenda and rules of conduct were reviewed, including voting and Q&A procedures.
Board and executive committee updates
Board members and key executives, including the CEO, CFO, General Counsel, and VP of Investor Relations, were introduced.
Corporate governance
Paul Ramirez of Broadridge was appointed Inspector of Election and signed the customary oaths.
A quorum was confirmed, allowing the meeting to proceed with official business.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bioventus
- Q2 2026 revenue up 4%, strong Pain Treatments, strategic review, and guidance reaffirmed.BVS
Q2 2026 - 2026 guidance targets $605M revenue, margin expansion, and growth from PNS, PRP, and global markets.BVS
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Q1 2026 saw 7% revenue growth, higher margins, and raised full-year earnings guidance.BVS
Q1 2026 - Vote on 12 director nominees and auditor ratification at the June 2026 virtual annual meeting.BVS
Proxy filing - Shareholders to elect twelve directors and ratify auditor amid strong growth and governance focus.BVS
Proxy filing - Strong growth, margin expansion, and cash flow drive value across a $6.4B market.BVS
Corporate presentation - Q4 2025 saw 10% organic growth, record cash flow, and strong 2026 growth guidance.BVS
Q4 2025 - Q2 revenue up 10.3%, guidance raised, with $31.9M impairment and litigation settlement.BVS
Q2 2024 - Q3 revenue up 15% year-over-year, guidance raised, and divestiture to reduce debt.BVS
Q3 2024